<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="75487">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01828944</url>
  </required_header>
  <id_info>
    <org_study_id>AU961</org_study_id>
    <secondary_id>2012-A00344-39   [N°IDRCB]</secondary_id>
    <nct_id>NCT01828944</nct_id>
  </id_info>
  <brief_title>Olive Oil Polyphenols, Vitamin D, Docosahexaenoic Acid (DHA) and Locomotor Function (PolivD3)</brief_title>
  <acronym>PolivD3</acronym>
  <official_title>Olive Oil Polyphenols, Vitamin D and Docosahexaenoic Acid (DHA) Synergistic Effects on Locomotor Function</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Lesieur</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Institut National de la Recherche Agronomique</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Centre de Recherche en Nutrition Humaine d'Auvergne</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Lesieur</source>
  <oversight_info>
    <authority>France : National Health Products Safety Agency</authority>
    <authority>France: Ministry of Health</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The present project hypothesizes that the potential protective effect of olive oil relies on
      its polyphenols profile (quality and quantity) and that it may be synergistic to other food
      components. Among the nutrients that may be of interest for bone and muscle tissues,
      unsaturated fatty acids and vitamins are the most described.

      Consequently, based on the promising available preliminary data, the present project aims to
      investigate the possible preventive effect of olive oil polyphenols and eventually the
      synergistic effects of fatty acids and vitamin D on bone, muscle and adipose tissue, in
      order to prevent any locomotor dysfunction.

      Volunteers will be supplemented during 9 months. The primary and secondary outcome measures
      will be performed at baseline, 3 and 9 months.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>December 2012</start_date>
  <completion_date type="Anticipated">December 2014</completion_date>
  <primary_completion_date type="Anticipated">July 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention</study_design>
  <primary_outcome>
    <measure>Changes in bone mineral density</measure>
    <time_frame>at baseline and after 9 months of supplementation</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Changes in serum markers of bone resorption</measure>
    <time_frame>At baseline, 3 and 9 months</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>changes in serum markers of bone formation</measure>
    <time_frame>At baseline, 3 and 9 months</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">150</enrollment>
  <condition>Osteopenia</condition>
  <condition>Sarcopenia</condition>
  <arm_group>
    <arm_group_label>Extra virgin olive oil</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Extra virgin olive oil</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Enriched extra virgin olive oil</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Enriched extra virgin olive oil</description>
  </arm_group>
  <arm_group>
    <arm_group_label>refined olive oil</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>refined olive oil</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>olive oil</intervention_name>
    <arm_group_label>Extra virgin olive oil</arm_group_label>
    <arm_group_label>Enriched extra virgin olive oil</arm_group_label>
    <arm_group_label>refined olive oil</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Caucasian female

          -  Within at least 7 years post-menopause

          -  Generally healthy as determined by standard medical assessment on physical and mental
             health

          -  Normal weight as determined by BMI (20≤ BMI ≤30)

          -  Affiliated to National Health Insurance

          -  Willing to comply with the study procedures

          -  Willing to accept use of all nameless data, including publication, and the
             confidential use and storage of all data

          -  Having received both oral and written explanations about the study

          -  Having provided her written informed consent

        Exclusion Criteria:

          -  Intestinal or severe metabolic diseases / disorders such as diabetes, renal, hepatic
             or pancreatic diseases / disorders, ulcer, hyperthyroidism, malignancy, chronic
             malnutrition

          -  Osteoporosis (defined by T-score of -2.5 standard deviation (SD) at hip and/or spine)

          -  On therapy with drugs known to interfere with bone and muscle metabolism

          -  Taking regular calcium and vitamin D supplements

          -  Currently participating or having participated in another clinical trial during past
             1 year prior to the beginning of this study, this depending on the type of previous
             study•

          -  Intense Physical activity
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>57 Years</minimum_age>
    <maximum_age>79 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Véronique Coxam, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Institut National de la Recherche Agronomique</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Véronique Coxam, PhD</last_name>
    <phone>+33(0)473624632</phone>
    <email>veronique.coxam@clermont.inra.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Nathalie Meunier, PhD</last_name>
    <phone>+33(0)473608253</phone>
    <email>nathalie.meunier@clermont.inra.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Centre de Recherche en Nutrition Humaine</name>
      <address>
        <city>Clermont Ferrand</city>
        <state>Auvergne</state>
        <zip>63000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nathalie Meunier, PhD</last_name>
      <email>nathalie.meunier@clermont.inra.fr</email>
    </contact>
    <contact_backup>
      <last_name>Noël Cano, MD, PhD</last_name>
      <email>noel.cano@clermont.inra.fr</email>
    </contact_backup>
    <investigator>
      <last_name>Noël Cano, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre d'investigation clinique</name>
      <address>
        <city>Marseille</city>
        <state>Bouche du Rhône</state>
        <zip>13005</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sophie Morange, MD</last_name>
      <phone>+33(0)491384120</phone>
      <email>sophie.morange@ap-hm.fr</email>
    </contact>
    <contact_backup>
      <last_name>Cecilia Mallmann</last_name>
      <phone>+33(0)491384119</phone>
      <email>cecilia.mallmann@ap-hm.fr</email>
    </contact_backup>
    <investigator>
      <last_name>Sophie Morange, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <link>
    <url>http://www1.clermont.inra.fr/crnh/</url>
  </link>
  <verification_date>April 2013</verification_date>
  <lastchanged_date>April 10, 2013</lastchanged_date>
  <firstreceived_date>April 2, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Vitamin D</keyword>
  <keyword>bone loss</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Bone Diseases, Metabolic</mesh_term>
    <mesh_term>Sarcopenia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Vitamin D</mesh_term>
    <mesh_term>Ergocalciferols</mesh_term>
    <mesh_term>Vitamins</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
